营业时间
-
星期日
休息日
-
星期一
9:00 AM - 5:30 PM
-
星期二
9:00 AM - 5:30 PM
-
星期三
9:00 AM - 5:30 PM
-
星期四
9:00 AM - 5:30 PM
-
星期五
9:00 AM - 5:30 PM
-
星期六
休息日
公司资讯
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.
Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patent applications. Incannex is listed on the Australian Stock Exchange (ASX) with stock code “IHL” and has American Depository Shares listed on NASDAQ under code “IXHL”.
团队组成
Joel Latham
Incannex Healthcare Limited
Norwest, Unit 105, 8 Century Circuit
Joel Latham
热门服务
Incannex Healthcare
60 分钟
Incannex Healthcare Limited
Norwest, Unit 105, 8 Century Circuit
Incannex Healthcare
评论
0 客户评论